---
layout: default
title: Thyrotropin Alfa
parent: Model Prediction Only (L5)
nav_order: 772
evidence_level: L5
indication_count: 10
---

# Thyrotropin Alfa
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Thyrotropin Alfa: From Original Indication (Data Unavailable) to Predicted Migraine Disorder

## One-Sentence Summary

Thyrotropin alfa (rhTSH, DrugBank DB00024) currently has no approved indication data or mechanism-of-action information available in this Evidence Pack, and it is not marketed in Canada. The TxGNN model's top prediction is **Migraine Disorder** (score 99.98%), but this ranks at evidence level **L5** — no clinical trials and no literature support the association, and the model's own rationale flags it as a high-scoring embedding artifact with no known mechanistic basis.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no approved indication text in this Evidence Pack |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Mechanism-of-action data for thyrotropin alfa is not currently available in this Evidence Pack (flagged as data gap DG002, High severity), and no approved original indication text is on file either. Without this baseline information, an independent mechanistic-plausibility assessment cannot be constructed for the drug in general.

For the top-ranked candidate specifically, the evidence pack's own repurposing rationale is explicit and should be taken at face value: *"TSH receptor agonism has no known association with migraine pathophysiology (trigeminovascular system, CGRP pathway) — this is purely a high-scoring KG embedding output with no mechanistic support."* In other words, the 99.98% score reflects the knowledge-graph embedding geometry, not a biologically grounded drug–disease signal.

This pattern is not isolated to the top prediction. Across the ten candidates in this pack, the recurring findings are: (a) most (7/10) have **zero** clinical trials or literature (L5), (b) one candidate with 20 literature hits (rank 4, "migraine with or without aura, susceptibility to") turned out to be a keyword mismatch — the retrieved papers are entirely about epilepsy genetics, unrelated to thyrotropin alfa or migraine, and (c) the one candidate with real, drug-relevant clinical trials (rank 10, hyperthyroidism) is mechanistically **contradictory**: thyrotropin alfa is a TSH-receptor agonist that stimulates thyroid hormone release, making it a plausible *aggravating* factor for hyperthyroidism rather than a treatment for it, and the matched trials actually evaluate rhTSH as radioiodine pretreatment for goiter, not hyperthyroidism therapy. Taken together, this Evidence Pack does not currently support a credible repurposing signal for thyrotropin alfa in any of its top 10 predicted indications.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Thyrotropin alfa is not currently marketed in Canada (market status: Not marketed / Not Marketed); no DIN records are available (`total_licenses: 0`).

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: Warning and contraindication data collection from TFDA is currently marked as a blocking data gap — DG001 — pending label retrieval and parsing before any safety-stage evaluation can proceed.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
None of the top 10 TxGNN-predicted indications for thyrotropin alfa are supported by credible clinical or literature evidence. Evidence is either entirely absent (7/10 candidates, L5), contaminated by keyword-mismatched literature unrelated to the drug (e.g., epilepsy genetics papers retrieved for a migraine-susceptibility term), or mechanistically contradictory to the drug's known agonist pharmacology (hyperthyroidism candidate). This aligns with the evidence pack's own per-candidate "Hold" recommendations at decision stage S0/S1.

**To proceed, the following is needed:**
- Original approved indication data for thyrotropin alfa (currently entirely missing from this pack)
- Mechanism-of-action data via DrugBank API query (DG002)
- TFDA label PDF retrieval and parsing for warnings/contraindications (DG001, blocking for any safety-stage progression)
- Re-run evidence collection with tighter drug-specific query terms to eliminate keyword-mismatch contamination (notably for the "migraine susceptibility" and interferon-related literature sets)
- Expert pharmacological review before advancing any candidate past S0, given the mechanistic contradiction identified for the hyperthyroidism candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

